At present, no PET molecular biomarker is pathognomonic of depression, but the composite of results with various tracers might eventually serve to identify molecular sub-types of the disorder, and further investigation might test the hypothesis that there is spatial overlap between increased TSPO binding and altered markers of serotonin innervation and metabolism, or other established molecular imaging results. Here, TSPO is linked to depressive disorder.